Correlation between FGF23 level and outcome in patients with heart failure

Objective To investigate the effect of fibroblast growth factor 23 (FGF23) on mortality and hospitalization risk in patients with heart failure. Methods The hospitalization examination results, all-cause death and re-hospitalization data of 252 patients with heart failure in our hospital form 2016 to 2017 were retrospectively analyzed. The plasma FGF23 levels in the 252 patients were measured. The association between FGF23 and the results was analyzed by Cox regression analysis. Results The plasma fibroblast growth factor 23 level was higher in the patients with high NYHA classification (P<0.05); the proportion of HFPEF in the patients with a high fibroblast growth factor 23 level was significantly higher than that in those with a low level (P<0.05). In addition, highFGF23 was associated with aldosterone, renin and hemoglobin levels. Multivariate Cox regression analysis showed that the overall endpoint of all-cause mortality and hospitalization for heart failure increased risk 1.15 (1.08-1.22) per logarithm (P<0.05). Conclusion For patients with new-onset and worsening heart failure, elevated plasma FGF23 level is associated with volume overload, and the risk of hospitalization for all-cause death and heart failure increases. Key words: FGF23; Heart failure; All-cause death